Opinion|Videos|January 20, 2025
Diagnosing Tardive Dyskinesia
Panelists discuss how clinicians rely on careful observation, standardized rating scales like the AIMS (Abnormal Involuntary Movement Scale), and comprehensive patient histories to diagnose tardive dyskinesia, while facing challenges in distinguishing it from other movement disorders due to symptom overlap and the need to rule out conditions like drug-induced parkinsonism, akathisia, and primary movement disorders.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- What methods or tests are commonly used to diagnose TD in clinical practice, and what are the challenges associated with diagnosing TD, including differentiating it from other movement disorders?
Advertisement
Related to this article
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
New warnings cover every GLP-1 RA, including semaglutide, tirzepatide, and orforglipron.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
4
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
5